75N95022Q00250

Submitted by pluggern on Tue, 05/17/2022 - 08:36
Post Date/ Solicitation Issue Date
Closing Response Date
Proposed Award Date
Project Title
Cisbio HTRF cAMP Gs Dynamic Kit (Brand-name or equal)
Contracting Office
National Institute on Drug Abuse (NIDA)

Contact Points

Primary Contract Specialist

Renato
Gomes
renato.gomes@nih.gov
NAICS Code Number
325414
Biological Product (Except Diagnostic) Manufacturing
Small Business Size Standard
1250 employees
FPDS Classification Code
6505 - Drugs And Biologicals
Delivery of Goods
Four (4) weeks after receipt of order (ARO)
Set-Aside Status
Not Set Aside
Competition Status
Brand Name or Equal
Brand Name
For reference purposes, the Assay Kit that meets the need of this requirement is the Cisbio HTRF cAMP Gs Dynamic Kit.
Rationale/ Salient Characteristics
For reference purposes, the Assay Kit that meets the need of this requirement is the Cisbio HTRF cAMP Gs Dynamic Kit (Brand-name or equal), as follows:
• HTRF® cAMP Gi Assay kit 100,000 tests, Part Number: 62AM9PEJ, Quantity: 1 ea.
• HTRF® cAMP Gs Dynamic Assay kit 20,000 tests, Part Number: 62AM4PEC, Quantity: 2 ea.

The salient characteristics of the Assay Kits include:
o Homogeneous assay
o Ratiometric readout
o Anti-cAMP antibodies available with different affinities toward cAMP for desired assay sensitivities
o Does not require any recombinant protein expression for detection
o Permits absolute quantification of cellular cAMP level by means of a standard curve
o Measure cAMP in a non-separation, high throughput format.
o Able to be miniaturized into 1536 well plate format for high-throughput screening
o Easy handling without washing steps.
Background/Description of Requirement

The National Institutes of Health (NIH) is the nation’s leading medical research agency and the primary Federal agency whose mission is to seek fundamental knowledge about the nature and behavior of living systems and the application of that knowledge to enhance health, lengthen life, and reduce illness and disability, conducting, supporting and making medical discoveries that improve people’s health and save lives.

NCATS is one of 27 Institutes and Centers at the NIH and its mission is to catalyze the generation of innovative methods and technologies that will enhance the development, testing and implementation of diagnostics and therapeutics across a wide range of human diseases and conditions..

NCATS is pursing small molecule probes targeting Adenylyl Cyclase 1 (AC1) as opioid alternative for chronic and inflammatory pain. Using stable AC1 overexpressing cell lines for screening, and AC8 overexpressing cell lines for counterscreening, NCATS intends to miniaturize an assay into a high-throughput 1536 well format to rapidly screen and identify AC1 inhibitors.

As provided in the NIH Assay Guidance Manual[1],

“Cyclic adenosine monophosphate (cAMP) is an important intracellular second messenger in GPCR signal transduction” Agonist activation of GPCRs that couple to the Gαs protein leads to an increased production of intracellular cAMP levels, whereas activation of GPCRs that couple to the Gαi protein leads to reduced production of intracellular cAMP levels”

In order to perform the studies, NCATS miniaturized the assay to adapt for high throughput screening of adenyl cyclase 1 using NCATS chemical libraries. Using the cAMP HTRF kit is important to show reproducibility of data from previous studies and the inclusion of previously identified positive controls which is essential for data analysis. Moreover, the sensitivity and varying affinities of the cAMP antibodies specifically associated with the cAMP HTRF assay kit enables the scientists to use the assay for counterscreening targeting different adenyl cyclases.

In this case, NCATS shall use the HTRF (Homogeneous Time Resolved Fluorescence) assay technology to measure cAMP in a non-separation, high throughput format intended for the direct quantitative determination of cAMP. This assay technology has been vetted by NIH on the NIH Assay Guidance Manual1 and has successfully been used to screen several large libraries in 1536 well format with high reproducibility and low false positives at NCATS.

Thus, without acquisition of the Cisbio HTRF cAMP Gs Dynamic Kit (Brand-name or equal), NCATS will be unable to advance the research of adenylyl cyclase 1 (AC1) for pain management as part of the HEAL (Helping to End Addiction Long-term) initiative.

 

[1] Wang T, Li Z, Cvijic ME, et al. Measurement of cAMP for Gαs- and Gαi Protein-Coupled Receptors (GPCRs) 2017 Nov 20. In: Markossian S, Grossman A, Brimacombe K, et al., editors. Assay Guidance Manual [Internet]. Bethesda (MD): Eli Lilly & Company and the National Center for Advancing Translational Sciences; 2004-. Available from: https://www.ncbi.nlm.nih.gov/books/NBK464633/

Interested parties may identify in writing their interest and capability in response to this requirement. Responses to this notice shall contain sufficient information to establish the interested parties’ bona-fide capabilities for fulfilling the requirement and include: unit price, list price, shipping and handling costs, the delivery period after contract award, the prompt payment discount terms, the F.O.B. Point (Destination or Origin), the Dun & Bradstreet Number (DUNS), the Taxpayer Identification Number (TIN), and the certification of business size. All offerors must have an active registration in the System for Award Management (SAM) www.sam.gov.

All responses must be received by closing date and must reference the announcement. Responses may be submitted electronically to the attention of the contract specialist. Fax responses will not be accepted.

All responsible sources may submit a bid, proposal, or quotation which shall be considered by the agency.